{"acquisitions":[],"changes":[],"country":"FR","description":"ErVaccine Technologies develops therapeutic cancer vaccines and T-cell therapies that target tumor antigens derived from endogenous retroviruses. It aims to treat cancer patients by directing the immune system at a new family of non-conventional tumor antigens. Its endogenous-retrovirus target class opens vaccine and cell-therapy options beyond conventional antigens, spun out of Centre Léon Bérard in Lyon.","domain":"ervaccinetechnologies.com","employees":null,"founded":2019,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":45.764,"lng":4.8357,"location":"Lyon, France","multiples":[],"name":"ErVaccine Technologies","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":2700000,"connectionsAmong":[],"currency":"EUR","date":"2023-07-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"ervaccinetechnologies-com-2023-07-01-grant","source":{"fact":"round","publisher":"eu-grant","retrievedAt":"2026-05-07","status":"attributed","url":null},"status":"attributed","type":"grant","url":null}],"slug":"ervaccinetechnologies-com","sources":[{"fact":"round","publisher":"eu-grant","retrievedAt":"2026-05-07","status":"attributed","url":null},{"fact":"existence","publisher":"ervaccinetechnologies.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://ervaccinetechnologies.com"},{"fact":"description","publisher":"ervaccinetechnologies.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://ervaccinetechnologies.com"}],"stage":"seed","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":[],"totalRaisedUsd":4800000,"traction":[],"updatedAt":"2026-05-07","valuations":[]}